Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 432

1.

Bone marrow blast elimination by the fifth day of 7+3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C.

Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651. [Epub ahead of print] No abstract available.

PMID:
31591736
2.

Time Contribution of Social Workers in Care Management: Value for Older Adults.

Rowe JM, Rizzo VM, Kang SY, Kukowski R, Ewald B, Newman M, Golden R.

Prof Case Manag. 2019 Nov/Dec;24(6):306-316. doi: 10.1097/NCM.0000000000000305.

PMID:
31580298
3.

Newly diagnosed myeloma patients with low-burden disease may benefit from tandem autologous stem cell transplantation: results of long-term follow-up.

Benyamini N, Lavi N, Zuckerman T, Aviv A, Rowe JM, Katz T.

Bone Marrow Transplant. 2019 Sep 16. doi: 10.1038/s41409-019-0671-5. [Epub ahead of print] No abstract available.

PMID:
31527816
4.

Ibrutinib associated invasive fungal diseases in patients with CLL and non-Hodgkin lymphoma: an observational study.

Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, Herishanu Y, Benjamini O, Tadmor T, Okamoto K, Arthurs B, Gottesman B, Kater AP, Talha M, Eichhorst B, Korem M, Bogot N, De Boer F, Rowe JM, Lachish T.

Mycoses. 2019 Sep 13. doi: 10.1111/myc.13001. [Epub ahead of print]

PMID:
31520441
5.

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30528-2. doi: 10.1016/j.bbmt.2019.08.014. [Epub ahead of print] Review.

PMID:
31446198
6.

Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.

Stone A, Zukerman T, Flaishon L, Yakar RB, Rowe JM.

Leuk Res. 2019 Jul;82:36-42. doi: 10.1016/j.leukres.2019.05.007. Epub 2019 May 21.

7.

Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.

Beyar-Katz O, Lavi N, Ringelstein-Harlev S, Henig I, Yehudai-Ofir D, Haddad N, Fineman R, Ofran Y, Nov Y, Sahar D, Moustafa-Hawash N, Rowe JM, Zuckerman T.

Leuk Lymphoma. 2019 Oct;60(10):2449-2456. doi: 10.1080/10428194.2019.1594214. Epub 2019 Apr 3.

PMID:
30943060
8.

The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.

Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, Saber W, de Lima M, Sandmaier BM, Uy G, Kamble RT, Cairo MS, Cooper BW, Cahn JY, Ganguly S, Camitta B, Verdonck LF, Dandoy C, Diaz MA, Savani BN, George B, Liesveld J, McGuirk J, Byrne M, Grunwald MR, Drobyski WR, Pulsipher MA, Abdel-Azim H, Prestidge T, Wieduwilt MJ, Martino R, Norkin M, Beitinjaneh A, Seo S, Nishihori T, Wirk B, Frangoul H, Bashey A, Mori S, Marks DI, Bachanova V.

Blood Adv. 2019 Feb 26;3(4):670-680. doi: 10.1182/bloodadvances.2018027003.

9.

Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study.

Frey N, Jang JH, Szer J, Illés Á, Kim HJ, Ram R, Chong BH, Rowe JM, Borisenkova E, Liesveld J, Winer ES, Cherfi A, Aslanis V, Ghaznawi F, Strickland S.

Lancet Haematol. 2019 Mar;6(3):e122-e131. doi: 10.1016/S2352-3026(18)30231-X. Epub 2019 Jan 29.

PMID:
30704923
10.

The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Medeiros BC, Othus M, Tallman MS, Sun Z, Fernandez HF, Rowe JM, Lazarus HM, Appelbaum FR, Luger SM, Litzow MR, Erba HP.

Leuk Res. 2019 Mar;78:29-33. doi: 10.1016/j.leukres.2019.01.007. Epub 2019 Jan 17.

11.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG.

Nat Genet. 2019 Feb;51(2):296-307. doi: 10.1038/s41588-018-0315-5. Epub 2019 Jan 14.

12.

Shifting therapeutic paradigms in induction and consolidation for older adults with acute myeloid leukemia.

Zuckerman T, Rowe JM.

Curr Opin Hematol. 2019 Mar;26(2):51-57. doi: 10.1097/MOH.0000000000000480.

PMID:
30585895
13.

Evaluation of an elective course for preparing students to pursue postgraduate residency training.

Hammond DA, Rowe JM, Wiley TL, Painter JT.

Curr Pharm Teach Learn. 2018 Sep;10(9):1264-1271. doi: 10.1016/j.cptl.2018.06.007. Epub 2018 Jun 28.

PMID:
30497630
14.

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.

Haematologica. 2019 Apr;104(4):e147-e150. doi: 10.3324/haematol.2018.197277. Epub 2018 Nov 22. No abstract available.

15.

Progress and predictions: AML in 2018.

Rowe JM.

Best Pract Res Clin Haematol. 2018 Dec;31(4):337-340. doi: 10.1016/j.beha.2018.09.002. Epub 2018 Sep 20. Review.

PMID:
30466743
16.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W.

Blood Adv. 2018 Nov 13;2(21):2922-2936. doi: 10.1182/bloodadvances.2018024844.

17.

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.

Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS.

Am J Hematol. 2019 Jan;94(1):111-117. doi: 10.1002/ajh.25333. Epub 2018 Nov 15.

PMID:
30370956
18.

Advances in the genetics of acute lymphoblastic leukemia in adults and the potential clinical implications.

Horowitz NA, Akasha D, Rowe JM.

Expert Rev Hematol. 2018 Oct;11(10):781-791. doi: 10.1080/17474086.2018.1509702. Epub 2018 Aug 16. Review.

PMID:
30092672
19.

Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.

Ganzel C, Kharit M, Duksin C, Rowe JM.

Haematologica. 2018 Oct;103(10):e489-e490. doi: 10.3324/haematol.2018.197640. Epub 2018 Jun 28. No abstract available.

20.

Sensitized photon upconversion in anthracene-based zirconium metal-organic frameworks.

Rowe JM, Zhu J, Soderstrom EM, Xu W, Yakovenko A, Morris AJ.

Chem Commun (Camb). 2018 Jul 10;54(56):7798-7801. doi: 10.1039/c8cc01893f.

PMID:
29946618
21.

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.

Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS.

Am J Hematol. 2018 Jun 15. doi: 10.1002/ajh.25162. [Epub ahead of print]

22.

Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.

Ganzel C, Rouvio O, Avivi I, Magen H, Jarchowsky O, Herzog K, Cohen Y, Tadmor T, Horwitz NA, Leiba M, Nagler A, Cohen Y, Bulvik S, Polliack A, Rowe JM, Gatt ME; Israeli Multiple Myeloma Study Group.

Leuk Res. 2018 May;68:9-14. doi: 10.1016/j.leukres.2018.02.010. Epub 2018 Mar 2.

PMID:
29501828
23.

Team-based care: Views from community health center staff.

Law KL, Rowe JM.

Soc Work Health Care. 2018 Apr;57(4):284-299. doi: 10.1080/00981389.2018.1438330. Epub 2018 Feb 12.

PMID:
29432080
24.

Revisiting autologous transplantation in acute myeloid leukemia.

Ganzel C, Rowe JM.

Curr Opin Hematol. 2018 Mar;25(2):95-102. doi: 10.1097/MOH.0000000000000408. Review.

PMID:
29324476
25.

Patient Outcomes Associated With Phenobarbital Use With or Without Benzodiazepines for Alcohol Withdrawal Syndrome: A Systematic Review.

Hammond DA, Rowe JM, Wong A, Wiley TL, Lee KC, Kane-Gill SL.

Hosp Pharm. 2017 Oct;52(9):607-616. doi: 10.1177/0018578717720310. Epub 2017 Jul 17.

26.

AML in 2017: Advances in clinical practice.

Rowe JM.

Best Pract Res Clin Haematol. 2017 Dec;30(4):283-286. doi: 10.1016/j.beha.2017.09.010. Epub 2017 Sep 22. Review.

PMID:
29156195
27.

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.

Tvito A, Rowe JM.

Expert Opin Biol Ther. 2017 Dec;17(12):1557-1564. doi: 10.1080/14712598.2017.1387244. Epub 2017 Nov 1. Review.

PMID:
29092647
28.

Which patients should I transplant with acute lymphoblastic leukemia?

Inbar T, Rowe JM, Horowitz NA.

Best Pract Res Clin Haematol. 2017 Sep;30(3):249-260. doi: 10.1016/j.beha.2017.07.005. Epub 2017 Jul 13. Review.

PMID:
29050698
29.

Allogeneic stem-cell transplantation for myelofibrosis.

Lavi N, Rowe JM, Zuckerman T.

Curr Opin Hematol. 2017 Nov;24(6):475-480. doi: 10.1097/MOH.0000000000000381. Review.

PMID:
28832353
30.

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

Litzow MR, Fielding AK, Luger SM, Paietta E, Ofran Y, Rowe JM, Goldstone AH, Tallman MS, Lazarus HM.

Bone Marrow Transplant. 2017 Dec;52(12):1592-1598. doi: 10.1038/bmt.2017.110. Epub 2017 Jun 5. Review.

PMID:
28581459
31.

Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.

Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta EM, Rowe JM, Vance GH, Wiernik P, Wiktor AE, Zhang Y, Tallman MS; ECOG-ACRIN Cancer Research Group.

Leuk Res. 2017 Aug;59:55-64. doi: 10.1016/j.leukres.2017.05.010. Epub 2017 May 12.

32.

Making the most of advanced pharmacy practice experiences.

Wiley TL, Rowe JM, Hammond DA.

Am J Health Syst Pharm. 2017 May 15;74(10):648-651. doi: 10.2146/ajhp160202. No abstract available.

PMID:
28483944
33.

Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.

Ronson A, Tvito A, Rowe JM.

Curr Treat Options Oncol. 2017 Mar;18(3):20. doi: 10.1007/s11864-017-0455-3. Review.

PMID:
28382538
34.

Published abstracts at international meetings often over- or underestimate the initial response rate.

Beyar-Katz O, Rowe JM, Townsend LE, Tallman MS, Hadomi R, Horowitz NA.

Blood. 2017 Apr 20;129(16):2326-2328. doi: 10.1182/blood-2017-01-763144. Epub 2017 Mar 6. No abstract available.

PMID:
28264800
35.

Synergistic antileukemic therapies in NOTCH1-induced T-ALL.

Sanchez-Martin M, Ambesi-Impiombato A, Qin Y, Herranz D, Bansal M, Girardi T, Paietta E, Tallman MS, Rowe JM, De Keersmaecker K, Califano A, Ferrando AA.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2006-2011. doi: 10.1073/pnas.1611831114. Epub 2017 Feb 7.

36.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.

Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W.

Biol Blood Marrow Transplant. 2017 May;23(5):767-775. doi: 10.1016/j.bbmt.2017.01.078. Epub 2017 Jan 20.

37.

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, Laumann K, Rowe JM, Erba H, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS.

Blood. 2017 Mar 30;129(13):1763-1767. doi: 10.1182/blood-2016-10-747170. Epub 2017 Jan 12.

38.

AML in 2016: Where we are now?

Rowe JM.

Best Pract Res Clin Haematol. 2016 Dec;29(4):315-319. doi: 10.1016/j.beha.2016.10.001. Epub 2016 Oct 18. Review.

PMID:
27890252
39.

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, Pei D, Iacobucci I, Valentine M, Pounds SB, Shi L, Li Y, Zhang J, Cheng C, Rambaldi A, Tosi M, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Wiernik PH, Bhatia R, Aldoss I, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Mullighan CG.

J Clin Oncol. 2017 Feb;35(4):394-401. doi: 10.1200/JCO.2016.69.0073. Epub 2016 Nov 21.

40.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

41.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.

Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I, Shao Y, Chen IM, Valentine M, Pei D, Mungall KL, Mungall AJ, Ma Y, Moore R, Marra M, Stonerock E, Gastier-Foster JM, Devidas M, Dai Y, Wood B, Borowitz M, Larsen EE, Maloney K, Mattano LA Jr, Angiolillo A, Salzer WL, Burke MJ, Gianni F, Spinelli O, Radich JP, Minden MD, Moorman AV, Patel B, Fielding AK, Rowe JM, Luger SM, Bhatia R, Aldoss I, Forman SJ, Kohlschmidt J, Mrózek K, Marcucci G, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Paietta E, Willman CL, Loh ML, Hunger SP, Mullighan CG.

Nat Commun. 2016 Nov 8;7:13331. doi: 10.1038/ncomms13331.

42.

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.

Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Waanders E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrózek K, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG; St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project.

Nat Genet. 2016 Dec;48(12):1481-1489. doi: 10.1038/ng.3691. Epub 2016 Oct 24.

43.

Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.

Kumar AJ, Gimotty PA, Gelfand JM, Buck G, Rowe JM, Goldstone AH, Fielding A, Marks DI, Litzow M, Paietta E, Lazarus HM, Tallman MS, Luger SM, Loren AW.

Am J Hematol. 2016 Nov;91(11):1107-1112. doi: 10.1002/ajh.24497. Epub 2016 Aug 22. Erratum in: Am J Hematol. 2017 May;92 (5):E85.

44.

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh M, Kantarjian H.

Blood Cancer J. 2016 Sep 23;6(9):e473. doi: 10.1038/bcj.2016.84.

45.

Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.

Baljevic M, Dumitriu B, Lee JW, Paietta EM, Wiernik PH, Racevskis J, Chen C, Stein EM, Gallagher RE, Rowe JM, Appelbaum FR, Powell BL, Larson RA, Coutré SE, Lancet J, Litzow MR, Luger SM, Young NS, Tallman MS.

Acta Haematol. 2016;136(4):210-218. Epub 2016 Sep 16.

46.

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, Chia V, Doubek M, Giebel S, Hoelzer D, Ifrah N, Katz A, Kelsh M, Martinelli G, Morgades M, O'Brien S, Rowe JM, Stieglmaier J, Wadleigh M, Kantarjian H.

Haematologica. 2016 Dec;101(12):1524-1533. Epub 2016 Sep 1.

47.

Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008.

Ganzel C, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta EM, Litzow MR, Lee JW, Luger SM, Lazarus HM, Cripe LD, Wiernik PH, Tallman MS.

J Clin Oncol. 2016 Oct 10;34(29):3544-3553. Erratum in: J Clin Oncol. 2017 Jan 10;35(2):263.

48.

AIMS: A Care Coordination Model to Improve Patient Health Outcomes.

Rizzo VM, Rowe JM, Shier Kricke G, Krajci K, Golden R.

Health Soc Work. 2016 Aug 1;41(3):191-195. doi: 10.1093/hsw/hlw029. No abstract available.

49.

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.

Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W.

Cancer. 2016 Oct;122(19):3005-3014. doi: 10.1002/cncr.30140. Epub 2016 Jun 17.

50.

How I treat acute myeloid leukemia presenting with preexisting comorbidities.

Ofran Y, Tallman MS, Rowe JM.

Blood. 2016 Jul 28;128(4):488-96. doi: 10.1182/blood-2016-01-635060. Epub 2016 May 27. Review.

Supplemental Content

Support Center